Targeting B-cell malignancies with the beta-emitting anti-CD37 radioimmunoconjugate 177Lu-NNV003.

Astri Fjelde MaalandHelen HeyerdahlAdam O'SheaBergthora EiriksdottirVéronique PascalJan Terje AndersenArne KolstadJostein Dahle

Published in: European journal of nuclear medicine and molecular imaging (2019)

177Lu-NNV003 had a significant anti-tumour effect and a favourable toxicity profile. These results warrant further clinical testing in patients with CD37-expressing B cell malignancies.

Keyphrases

nk cells
oxidative stress
quantum dots
cancer therapy
fluorescent probe
wild type